🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Humira 40 mg solution for injection in pre-filled syringe, Lutikizumab, Humira 80 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Lutikizumab, Humira 40 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  2. Hydroxypropyl Guar Galactomannan

    Alcon Laboratories (Australia) Pty Ltd

    Dry Eye Disease

    phase 2 small molecule completed

    1 trial

  3. IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, Faslodex 250 mg solution for injection., JZP598

    Jazz Pharmaceuticals Ireland Limited

    Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer

    phase 2 small molecule active

    1 trial

  4. IBRANCE 75 mg hard capsules, EXEMESTANE, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, TAMOXIFEN, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, IBRANCE 125 mg hard capsules, ANASTROZOLE, IBRANCE 75 mg hard capsules, CYCLOPHOSPHAMIDE, DOCETAXEL, IBRANCE 100 mg hard capsules, IBRANCE 100 mg film-coated tablets, IBRANCE 100 mg hard capsul

    Ningbo Cancer Hospital

    Localized ER+ breast cancer

    phase 2 small molecule active

    1 trial

  5. IDARUBICIN, FLUDARABINE, CYTARABINE, DAUNORUBICIN, MITOXANTRONE, ETOPOSIDE, PKC412

    Novartis Pharmaceuticals

    untreated FLT3-mutated Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  6. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Unresectable/metastatic Small cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  7. IFOSFAMIDE , MabThera 500 mg concentrate for solution for infusion, ETOPOSIDE , Gazyvaro 1,000 mg concentrate for solution for infusion., CD20 CD3 TCB, RoActemra 20 mg/mL concentrate for solution for infusion, CARBOPLATIN

    Hoffmann-La Roche

    CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  8. IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  9. ILT-101 liquide, Placebo of ILT-101, CICLOSPORIN

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  10. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients With Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  11. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    unresectable stage III NSCLC (Non–small-cell lung cancer)

    phase 2 small molecule active

    1 trial

  12. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)

    phase 2 small molecule active

    1 trial

  13. IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB, IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  14. IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE , TREMELIMUMAB

    The George Institute

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  15. IMFINZI 50 mg/mL concentrate for solution for infusion., Ceralasertib, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil 250 mg Capsules

    AstraZeneca AB

    Unresectable or Advanced Melanoma

    phase 2 small molecule active

    1 trial

  16. IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

  17. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  18. IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutations and Early Stage HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  19. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  20. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    The George Institute

    Intermediate stage hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  21. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  22. INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE

    Hoffmann-La Roche

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  23. INC280, INC280, JNJ-61186372

    Janssen-Cilag International N.V.

    Unresectable Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. INCAGN02385, Retifanlimab (INCMGA00012), INCAGN02390

    Incyte

    In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources